OSCR

Atorvastatin Shows Limited Disease-Modifying Effects in an A53T α-Synuclein Mouse Model of Parkinson's Disease.

Overview

Authors: Lijian Wei1, Junkai Hua2, Shuangfeng Tang3, Jianming Lei1, Guozhi Li1, LiWei Wei4, MingShu Mo5
  1. Department of Geriatrics, Maoming People’s Hospital, Maoming, Guangdong China
  2. Guangzhou Medical University, Guangzhou, Guangdong China
  3. Department of Oncology I, Maoming People’s Hospital, Maoming, Guangdong China
  4. Department of Emergency, Guangdong Provincial Farm Reclamation Central Hospital, Zhanjiang, Guangdong China
  5. Department of Neurology, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong China
Journal: Neurotoxicity research, volume 44, issue 5, article 51
Dates: received 10 March 2026; accepted 19 August 2026; published online 9 September 2026; in print 2026
Type: Research article · Language: English
License: CC BY
Identifiers: DOI 10.1007/s12640-026-00825-y · PMID 42714756 · PMCID PMC13558405 · OpenAlex W7212032704
Open access: hybrid, a free copy (OpenAlex)
Categories: genetics / omics (modality), human (organism), mouse (organism), Parkinson's (population), cellular / molecular (subfield)
Methods: Statistics, fMRI & imaging
Keywords: Parkinson’s disease, α-Synuclein, Atorvastatin, Molecular docking, Transcriptomics
MeSH: alpha-Synuclein*, Atorvastatin*, Hydroxymethylglutaryl-CoA Reductase Inhibitors*, Parkinson Disease*, Parkinsonian Disorders*, Animals, Disease Models, Animal, Humans, Male, Mice, Mice, Transgenic, Molecular Docking Simulation (* major topic)
Topic: Parkinson's Disease Mechanisms and Treatments (Clinical Neurology, Medicine), according to OpenAlex
Funding: Guangdong Provincial Medical Research Fund (A2025081); Guangdong Provincial Science and Technology Planning Project (2023B110009)
Citations: not cited yet (Europe PMC); 37 references in the paper

Abstract

Neuroprotective effects of statins in Parkinson’s disease (PD) remain uncertain, and their activity in genetic α-synuclein (αSyn) disease models has been insufficiently characterized. We evaluated atorvastatin (ATO) in a mouse model with nigral overexpression of human A53T-mutant αSyn. Mice received ATO by oral gavage at 10 mg/kg/day for 5 weeks and were assessed using behavioral testing, neuropathological assessment, brain transcriptomics, and molecular docking. ATO inhibited cholesterol biosynthesis-related transcriptional programs and broadly remodeled lipid metabolism-associated networks, but did not lead to functional or histopathological benefit. ATO did not ameliorate motor deficits, restore dopaminergic markers, or reduce αSyn protein levels or pSer129-αSyn immunoreactivity. Transcriptomic analysis further showed that ATO failed to reverse the core disease-associated signature induced by A53T αSyn overexpression and instead increased SNCA mRNA. Targeted RNA-seq and western blot analyses showed no parallel increase in Prkn, Gba1, or Lamp2 transcript abundance or in PARKIN, GBA1, or LAMP2A protein expression. Molecular docking, used here as an exploratory structural comparison, suggested a relatively weak predicted interaction between ATO and αSyn when compared with several other statins and provided supportive context for the lack of efficacy. Overall, our findings indicate limited efficacy of ATO in this αSyn-driven setting and support further comparative evaluation of individual statins across complementary PD models.

Supplementary Information: The online version contains supplementary material available at https://doi.org/10.1007/s12640-026-00825-y.

Reproduced under the paper's license (CC BY), from the paper cited above.

Code

The paper links to its data and to no code of its authors: see the Data section.

Tracing map

A tracing map links a paper to the code its authors published: this paper has none, so it has no map.

Data

Datasets cited

Data Availability

All data collections employed and analyzed for the purposes of this research are available from the corresponding author on request from qualified investigators.

Reproduced under the paper's license (CC BY), from the paper cited above.

Versions

The history of this record: each version stored by the harvester or made by a correction of its authors or of the maintainers of its code, and what changed in its facts. The texts of the paper (its abstract, its availability statements) are not part of it; versions that changed only those are not listed.

Version 3, 28 September 2026

  • Publisher: n/a → Springer Science+Business Media

Version 1, 27 September 2026: the first record

Recorded: type, language, journal, volume, issue, pages, dates, 7 authors, 5 keywords, 12 MeSH terms, 2 funders, 37 references.

Cite

This paper

Wei, L., Hua, J., Tang, S., Lei, J., Li, G., Wei, L., & Mo, M. (2026). Atorvastatin Shows Limited Disease-Modifying Effects in an A53T α-Synuclein Mouse Model of Parkinson's Disease. Neurotoxicity research, 44(5), 51. https://doi.org/10.1007/s12640-026-00825-y

BibTeX

@article{wei2026atorvastatin,
author = {Wei, Lijian and Hua, Junkai and Tang, Shuangfeng and Lei, Jianming and Li, Guozhi and Wei, LiWei and Mo, MingShu},
title = {{Atorvastatin Shows Limited Disease-Modifying Effects in an A53T α-Synuclein Mouse Model of Parkinson's Disease}},
journal = {Neurotoxicity research},
year = {2026},
month = sep,
volume = {44},
number = {5},
pages = {51},
publisher = {Springer Science+Business Media},
issn = {1029-8428},
doi = {10.1007/s12640-026-00825-y},
url = {https://doi.org/10.1007/s12640-026-00825-y},
pmid = {42714756},
pmcid = {PMC13558405}
}

RIS

TY - JOUR
AU - Wei, Lijian
AU - Hua, Junkai
AU - Tang, Shuangfeng
AU - Lei, Jianming
AU - Li, Guozhi
AU - Wei, LiWei
AU - Mo, MingShu
TI - Atorvastatin Shows Limited Disease-Modifying Effects in an A53T α-Synuclein Mouse Model of Parkinson's Disease
T2 - Neurotoxicity research
J2 - Neurotox Res
PY - 2026
DA - 2026/09/09
VL - 44
IS - 5
SP - 51
SN - 1029-8428
PB - Springer Science+Business Media
DO - 10.1007/s12640-026-00825-y
UR - https://doi.org/10.1007/s12640-026-00825-y
LA - en
ER -

CSL-JSON

{
"id": "10.1007/s12640-026-00825-y",
"type": "article-journal",
"title": "Atorvastatin Shows Limited Disease-Modifying Effects in an A53T α-Synuclein Mouse Model of Parkinson's Disease",
"container-title": "Neurotoxicity research",
"author": [
{
"family": "Wei",
"given": "Lijian"
},
{
"family": "Hua",
"given": "Junkai"
},
{
"family": "Tang",
"given": "Shuangfeng"
},
{
"family": "Lei",
"given": "Jianming"
},
{
"family": "Li",
"given": "Guozhi"
},
{
"family": "Wei",
"given": "LiWei"
},
{
"family": "Mo",
"given": "MingShu"
}
],
"container-title-short": "Neurotox Res",
"volume": "44",
"issue": "5",
"page": "51",
"DOI": "10.1007/s12640-026-00825-y",
"PMID": "42714756",
"PMCID": "PMC13558405",
"ISSN": "1029-8428",
"publisher": "Springer Science+Business Media",
"URL": "https://doi.org/10.1007/s12640-026-00825-y",
"language": "en",
"issued": {
"date-parts": [
[
2026,
9,
9
]
]
}
}

Similar papers

The papers with a page that share the most with this one: the tools found in their code, their categories, datasets, cited references and authors, the rarest counting most.

[1] doi:10.1186/s13024-026-00951-3
Cholesterol metabolism in neurodegenerative diseases: mechanisms and therapeutic advances.
Journal: Molecular neurodegeneration
In common: cellular / molecular, 3 references
[2] doi:10.1186/s13024-025-00923-z [code]
Two lysosomal genes ATP13A2 and GBA1 interact to drive neurodegeneration.
Journal: Molecular neurodegeneration
In common: Parkinson's, genetics / omics, cellular / molecular, 3 references
[3] doi:10.1186/s40246-025-00898-4 [code]
Prioritizing missense mutations via a deep learning phosphorylation prediction model.
Journal: Human genomics
In common: uniprot.org/uniprotkb, Parkinson's, genetics / omics, cellular / molecular
[4] doi:10.1093/brain/awag039 [code]
Mapping the causal chain from genetic risk variants to lipid dysmetabolism in Parkinson's disease.
Journal: Brain : a journal of neurology
In common: Parkinson's, genetics / omics, 3 references
[5] doi:10.1016/j.chom.2024.02.011 [code]
Pathophysiology of chikungunya virus infection associated with fatal outcomes.
Journal: Cell host & microbe
In common: uniprot.org/uniprotkb, genetics / omics, cellular / molecular
[6] doi:10.3390/cells15151379
Extracellular Aβ42 Oligomers Induce ROCK2 Hyperactivation Through Dual Mediation by RhoA and GzmB: Significance of Moderate ROCK2 Activity in Neural Cells.
Journal: Cells
In common: uniprot.org/uniprotkb, mouse, cellular / molecular
[7] doi:10.1016/j.xcrm.2024.101546
Targeting low levels of MIF expression as a potential therapeutic strategy for ALS.
Journal: Cell reports. Medicine
In common: uniprot.org/uniprotkb, mouse, cellular / molecular
[8] doi:10.1038/s41467-024-50183-6
The mouse multi-organ proteome from infancy to adulthood.
Journal: Nature communications
In common: uniprot.org/uniprotkb, genetics / omics, mouse
[9] doi:10.1007/s10571-026-01706-w
Nitric Oxide Donor Alleviates Cardiac Arrest Induced Blood Brain Barrier Injury by Inhibiting HMGB1-ATG5 Mediated Endothelial Autophagy.
Journal: Cellular and molecular neurobiology
In common: uniprot.org/uniprotkb, mouse, cellular / molecular
[10] doi:10.3390/ph18101456
Shentong Zhuyu Decoction Alleviates Neuropathic Pain in Mice by Inhibiting the NMDAR-2B Receptor-Mediated CaMKII/CREB Signaling Pathway in GABAergic Neurons of the Interpeduncular Nucleus.
Journal: Pharmaceuticals (Basel, Switzerland)
In common: uniprot.org/uniprotkb, mouse, cellular / molecular

Contribute

The authors of this paper can claim it, correct its record and validate its tracing map, and the maintainers of its code (its owner, or a public member of its organization) correct what it says of their repository; anyone signed in can ask for its removal. Every request goes to OSCR's own machine, which answers it; your account page follows them.

Sign in with ORCID to claim this paper as one of its authors, correct its record or validate its tracing map: when the paper's metadata lists your ORCID iD, you are recognized at once. Maintainers of its code: sign in with GitHub, then claim the repository on your account page.

Request its removal

To ask OSCR to remove this record, the copies of its authors' scripts or its tracing map, use the removal request page: signed in, you say who you are, what to remove and why, then review and confirm the request. Published rules decide every request (how).

Discussion, reproductions, activity

Discussion: code errors and mismatches between the code and the paper about this paper and its code, from readers and its authors, beside the paper and its tracing map.

Reproductions: reports from readers who ran the authors' code and did not get the paper's result, what they ran, with which environment, commit and data.

Activity: what happens around this paper: new versions of its record, its map's validation, discussions and reproductions. It opens with sign-in.